Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 77 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed11981    
    Printed395    
    Emailed12    
    PDF Downloaded782    
    Comments [Add]    
    Cited by others 9    

Recommend this journal

 
ORIGINAL RESEARCH PAPERS
Year : 2006  |  Volume : 48  |  Issue : 4  |  Page : 238-242

Randomized controlled trial of standardized Bacopa monniera extract in age-associated memory impairment


1 Peninsula Community Mental Health Service, Frankston Hospital, Frankston, Victoria, Australia
2 Department of Psychiatry, KGMU Lucknow, Uttar Pradesh, India
3 Division of Clinical and Experimental Medicine, Central Drug Research Insitute, Lucknow, India

Correspondence Address:
Harjeet Singh
Department of Psychiatry, KG Medical University, Lucknow, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-5545.31555

Rights and Permissions

Background: Brahmi (Bacopa monniera) is a traditional Indian medicinal plant which causes multiple effects on the central nervous system. The standardized extract of this plant has shown enhanced behavioural learning in preclinical studies and enhanced information processing in healthy volunteers. Aim: To study the efficacy of standardized Bacopa monniera extract (SBME) in subjects with age-associated memory impairment (AAMI) without any evidence of dementia or psychiatric disorder. Methods: A double-blind, placebo-controlled randomized study design was employed. The subjects received either 125 mg of SBME or placebo twice a day for a period of 12 weeks followed by a placebo period of another 4 weeks (total duration of the trial 16 weeks). Each subject was evaluated for cognition on a battery of tests comprising mental control, logical memory, digit forward, digit backward, visual reproduction and paired associate learning. Results: SBME produced significant improvement on mental control, logical memory and paired associated learning during the 12-week drug therapy. Conclusion: SBME is efficacious in subjects with age-associated memory impairment.



[FULL TEXT] [PDF]*

        

Print this article         Email this article